novo nordisk weight loss drug - Search News

Novo Nordisk's next-gen obesity drug Cagrisema

Hosted on MSN · 1d

Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk defends next-gen obesity drug CagriSema, details new trial

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion from its market value.

Investopedia on MSN · 13d

Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.

Novo Nordisk beats in Q4

MarketWatch on MSN · 2d

Novo Nordisk sales beat estimates, but the story wasn’t Ozempic

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs.

Business Insider · 1d

NVO Earnings: Novo Nordisk Jumps on Healthy Sales Beat Driven by Wegovy

American depositary receipts (ADRs) of Novo Nordisk (NVO) jumped over 4% in pre-market trading this morning after reporting a healthy sales

Seeking Alpha on MSN · 1d

Novo Nordisk beats in Q4 as Wegovy sales more than double

Novo Nordisk (NVO) reported better-than-expected operating profits for Q4 2024 on Wednesday, thanks mainly to its GLP-1 drugs, including its popular weight loss therapy Wegovy, which added DKK 19.9B in sales,

1d

Weight loss pill could replace injections, would be transformative for millions

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

The weight-loss drugs being tested in 2025: will they beat Ozempic?

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results